Posture, Bone Density & Muscle: A Stanford Doctor Destroys Aging Myths Most People Believe

ELI5/TLDR

Dr. Deborah Kado — gerontologist, geriatrician, and co-director of the Stanford Longevity Center — spent the early part of her career proving that the more bent over you are by your 70s, the sooner you tend to die, mostly via lung-related causes. Her broader point: the things we accept as “normal aging” — slumped posture, brittle bones, a steady leak of muscle and power — are mostly preventable, sometimes reversible, and have well-known levers. The single biggest one is exercise; the most underrated one is purpose. The most overrated longevity supplement, in her view, is NAD.

The Full Story

How a Diet Coke became a research career

Kado fell into bone research almost by accident. As a medical student at Cornell during the AIDS years, she was haunted by patients she couldn’t save — including young people with curable cancers who simply couldn’t afford the treatment. When her chair told her to pick a research direction, she landed in the lab of Steve Cummings at UCSF, who handed her data on 10,000 women, all of them with spine X-rays, and told her to come up with a question.

She remembered a med-school lecture where a nephrologist had called her out for drinking Diet Coke in the second row — phosphoric acid, bad for bone. That became study one. Study two became the thing that defined her: linking vertebral fractures to mortality. She found that the more vertebral fractures a woman had — diagnosed or not, symptomatic or not — the more likely she was to die over the next eight years. Two-thirds of vertebral fractures are silent; people are walking around bent forward without knowing it.

Hyperkyphosis: the curve as a clock

The follow-up question was why these women were dying. They were dying disproportionately of pulmonary causes — COPD, pneumonia, blood clots in the lung. Kado’s instinct: if your spine collapses forward, your ribcage compresses your lungs. She replicated the mortality finding in a sub-cohort of 600 women whose posture had been measured directly. The more curved, the sooner they died. But only a third of the most-hunched women died of lung causes, which left a residual mystery she’s still chasing: hyperkyphosis is a marker of something deeper than osteoporosis alone.

“Regardless of the cause, the more hunched over you were, the more likely it was that you were going to be walking slower… you might even fall, you might get a fracture, and you’re more likely to pass away sooner.”

The bone-bank metaphor

Bone is built and lost on a lifetime curve. Peak around the early 30s. Steep drop for women through perimenopause and menopause; gentler slope for men. The strategy is to deposit as much as possible early, the same way you’d think about VO2 max — start higher, you stay above the threshold longer.

“If you’re super high, you may never get to the fracture threshold even if you fall.”

The deposit instructions are unsurprising: enough protein, enough calcium, vitamin D, fresh fruit and vegetables, and load-bearing exercise. Muscle and bone are in constant chemical conversation. Strong muscles pull on bone and tell it to stay dense.

Drugs work, and the Diane Sawyer problem

For people who arrive at menopause with a bad DEXA, Kado is matter-of-fact: the drugs work and they’re safer than most of the unproven things people inject themselves with. The bisphosphonates (alendronate / Fosamax, FDA-approved since 1995) reliably increase bone density and reduce fractures. The newer one, romosozumab (anti-sclerostin antibody, FDA-approved 2019), is the most impressive she’s seen: two shots in the arm once a month for a year, ~12% increase in spine bone density and significant hip gains, with reduced fracture risk across types.

She is irritated by the public’s allergy to bisphosphonates, which she traces to a 2008 Diane Sawyer segment about atypical femur fractures — a real but rare complication that mostly came from people staying on the drug forever, like a statin, with nobody monitoring. Used correctly, with breaks, the class is excellent. The IV form has even shown a mortality benefit in trials, possibly via the cholesterol pathway. Should everyone be on them? That’s been debated at the American Society for Bone and Mineral Research. Cummings argued no.

Power, not just strength

When Kado followed ~2,000 men with a mean age of 84 over a decade, the metric that best predicted who would not fracture was not grip strength. It was power — force times speed.

“Power is key, and that’s what we tend to lose more… two to three times as quick as strength.”

This matters because most strength training doesn’t train power. Power is the explosive bit — jumping, throwing, getting up out of a chair fast, catching yourself on a stumble. Bone gets measured easily with a DEXA, so it gets attention. Muscle is harder to standardize, so it lags. Her view: think in terms of a composite — strength, power, lean tissue.

It’s never too late

Around 1990, JAMA published a small study of nursing home residents in their late 80s and early 90s. Twelve weeks of high-intensity resistance work, three times a week with a trainer. CT scans of muscle fibre showed a 174% increase. They walked faster. They climbed stairs they couldn’t climb before.

“It just kind of proved the concept that even if you’re late to the party, you can still have a good time.”

Falls are the relevant scoreboard. Since 2000, the CDC has tracked a steady rise in fall-related deaths in adults over 60. Mortality after a hip fracture in women over 50 sits around 25% in the year after. One in six women over 50 will eventually have one.

The two scariest patient questions

Kado distinguishes “healthspan” — the WHO figure that puts the average American healthy life at 64 against an actual life expectancy of 79, leaving a 15-year tail of bad years — from “healthy longevity,” which she prefers because it allows for setbacks. A 45-year-old breast cancer survivor who reaches 80 living well isn’t a healthspan failure. She’s a healthy-longevity success.

When she asks Stanford undergraduates how long they’d want to live, the answers cluster around 80 — until she adds the qualifier “living independently.” Then everyone wants 100.

NAD, and the supplement question

Asked for the most overrated piece of longevity advice, she answers without hesitation: NAD. In every form — NMN, NR, IV.

“If you look at human trials… your blood levels go up. So must work. But they forget to advertise that everything that people care about — blood pressure, blood sugar, muscle function, just name it — no difference between the groups.”

The mouse studies are real. The human trials so far show a biomarker moving and nothing else. Most underrated thing for longevity, after exercise: purpose.

Key Takeaways

Hyperkyphosis predicts mortality independent of bone density. The more forward-curved, the worse the outcome — partly through pulmonary causes (lung compression), partly via something still unidentified.
Two-thirds of vertebral fractures are silent. They still raise mortality risk. Worth a spine X-ray if there’s a clinical reason to suspect.
Peak bone mass lands in the early 30s. Women lose steeply at perimenopause. Men decline gradually. Deposit early.
DEXA T-scores measure bone mineral density; they’re imperfect but currently the standard. Not a sentence — fracture history and family history matter more for risk.
Romosozumab (Evenity): ~12% spine BMD gain over one year, two arm shots monthly. Bisphosphonates (alendronate, etc.) remain workhorse and FDA-approved since 1995. Both reduce fractures.
Power declines 2–3× faster than strength with age. Train explosive movement (jumps, throws, stand-ups), not just slow heavy lifts. Force plates that measure jump power are useful kit if available.
174% muscle fibre gain in 90-year-olds after 12 weeks of supervised resistance training (JAMA, ~1990). The proof-of-concept that nothing about this is too late.
Falls are the leading injury-related cause of death in adults over 60. Hip fracture mortality at one year sits around 25%. One in six women over 50 will have one.
Composite to track: strength + power + lean tissue, not bone density alone.
Diet basics for bone: adequate protein, calcium, vitamin D, fruit and vegetables. Filtered coffee is fine, possibly better than unfiltered.
NAD precursors (NMN, NR): human trials show blood-level changes only, no functional outcomes yet.

Claude’s Take

This is a rare longevity podcast where the guest is more conservative than the host — and that’s the right ratio. Kado is a working geriatrician with 30+ years of follow-up data on the same cohorts, which makes her unusually well-positioned to call out fashion. The hyperkyphosis-mortality work is hers and is real. The romosozumab numbers are real and well-documented. The 174% nursing-home muscle finding is the famous Fiatarone study and has been replicated in spirit many times.

Where the host gets ahead of the data — “muscle and strength is a math problem now” — Kado quietly doesn’t agree. She keeps pulling back to the point that prediction of who declines is hard, that older populations get more heterogeneous not less, and that “I never write anybody off.” That’s the right epistemic posture.

The NAD line is worth pausing on. The mouse-vs-human gap in this space is enormous and most consumer messaging quietly elides it. Until a human trial shows something past blood-level enrichment — function, fractures, independence — it’s a biomarker product, not a longevity product. Same skepticism applies to the various hydrogels and exotic injectables; she politely refuses to opine on things that haven’t shown human efficacy.

The host’s “everyone should just be on bone drugs” pitch is interesting and Kado’s response is honest: it’s been debated, the answer is not yet. Some of that is the atypical-femur-fracture issue from indefinite use. Some is just clinical caution against drugging asymptomatic millions.

The single most actionable piece here is the power point. Most people who lift do strength but not power — slow heavy reps, no explosive work. The data say power is what protects against falls, and it’s the thing you lose first and fastest.